Gaucher Disease
📧 Sign up to get email alerts when something new happens for Gaucher Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-06-15FDA Approved: ELELYSO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Elelyso (taliglucerase alfa) from Pfizer Laboratories Div Pfizer Inc, indicating an approved mod…
-
FDA approval · 2016-06-08FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Cerezyme (imiglucerase) submitted by Genzyme Corporation.
-
FDA approval · 2016-04-21FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Cerezyme (imiglucerase) by Genzyme Corporation.
-
FDA approval · 2016-03-03FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Cerezyme (imiglucerase) from Genzyme Corporation.
-
FDA approval · 2016-02-25FDA Approved: ELELYSO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for ELELYSO (taliglucerase alfa) from Pfizer Laboratories Div Pfizer Inc. The approval involves …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease [Phase 3]
Multicenter extension study of taliglucerase alfa in pediatric Gaucher disease patients completed with posted results.
-
FDA approval · 2016-01-11FDA Approved: VPRIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for VPRIV (velaglucerase alfa) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: Auto-antibodies Prevalence and CD1 Role in Gaucher Disease
This clinical trial update reports results from a completed study evaluating the prevalence of auto-antibodies and the role of CD1 in Gauche…
-
FDA approval · 2015-12-23FDA Approved: ELELYSO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ELELYSO (taliglucerase alfa) submitted by Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2015-12-14Clinical Trial Update: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease [Phase 3]
A multicenter extension study of taliglucerase alfa in adults with Gaucher disease has completed phase 3.
-
CLINICAL_TRIALS trial_result · 2015-12-14Clinical Trial Update: Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease [Phase 3]
Phase 3 multicenter extension study of velaglucerase alfa in Japanese patients with Gaucher disease has completed with results posted.
-
FDA approval · 2015-11-20FDA Approved: ELELYSO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Elelyso (taliglucerase alfa) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA label_change · 2015-10-30FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Cerezyme (imiglucerase) from Genzyme Corporation, resulting in changes to the product labeling.
-
FDA approval · 2015-08-10FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for CEREZYME (imiglucerase) from Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2015-05-27Clinical Trial Update: Taste Evaluation of Different Liquid Formulations With Eliglustat [Phase 1]
A Phase 1 study evaluating taste and palatability of different liquid formulations of eliglustat in Gaucher disease.
-
FDA approval · 2015-05-11FDA Approved: CERDELGA — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for CERDELGA (Eliglustat) filed by Genzyme Corporation.
-
FDA approval · 2015-05-05FDA Approved: VPRIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for VPRIV (velaglucerase alfa) from Takeda Pharmaceuticals America, Inc., updating the drug's la…
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease [Phase 2]
Phase II randomized trial of alendronate for osteopenia in Gaucher disease patients completed.
-
FDA approval · 2015-03-09FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Cerezyme (imiglucerase) from Genzyme Corporation.
-
CLINICAL_TRIALS trial_result · 2015-02-04Clinical Trial Update: MR Spectroscopy and Disease Severity Score for Gaucher in Pediatric Population
This pediatric Gaucher disease trial evaluating MR spectroscopy and a disease severity score has completed, sponsored by the Children's Hosp…
-
FDA label_change · 2015-02-03FDA Approved: VPRIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for VPRIV (velaglucerase alfa) from Takeda Pharmaceuticals America, Inc., resulting in changes to th…
-
FDA approval · 2014-12-02FDA Approved: VPRIV — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for VPRIV (velaglucerase alfa) from Takeda Pharmaceuticals America, Inc. The approval pertains to a …
-
CLINICAL_TRIALS research · 2014-11-19Clinical Trial Update: Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C
Clinical trial update examining the immune response in patients with Gaucher disease and hepatitis C.
-
CLINICAL_TRIALS trial_result · 2014-11-11Clinical Trial Update: A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease [Phase 4]
Phase 4 trial evaluating two dose levels of taliglucerase alfa in pediatric Gaucher disease subjects; completed with results posted in 2014.
-
FDA approval · 2014-09-05FDA Approved: CEREZYME — Supplemental Application (Genzyme Corporation)
The FDA approved a supplemental application for Cerezyme (imiglucerase) submitted by Genzyme Corporation.